Product Reports Resources Pricing Login Book a demo

NGM Biopharmaceuticals

Biotech & Life Sciences · South San Francisco, United States · Founded 2007 · IPO 2019

A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases MoreLess

NGM Bio is a biopharmaceutical company dedicated to discovering and developing novel medicines aimed at transforming the lives of patients affected by serious diseases. The company employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to generate proprietary insights. These insights are used to create promising product candidates that can quickly advance into proof-of-concept studies. NGM Bio's research and development engine is highly productive, with all therapeutic candidates in its pipeline originating from its in-house discovery efforts. The company serves patients with unmet medical needs and operates in the biopharmaceutical market. NGM Bio's business model focuses on leveraging its scientific expertise to develop and commercialize new therapies, thereby generating revenue through the successful advancement and eventual market introduction of its drug candidates. Currently, the company has four programs in active clinical development, supported by a strong financial position and a healthy cash runway. Keywords: biopharmaceutical, drug discovery, protein engineering, disease biology, patient needs, clinical development, research, development, medicines, therapeutic candidates.

Revenue $12M
Total funding $100–500M

Talent graph

NGM Biopharmaceuticals's talent

Book a demo to see the people
Employees mapped 76 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 21 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on NGM Biopharmaceuticals's cap table

Sourced from Dealroom's funding history.

Series A 4 investors entered at this stage
The Column Group
Prospect Venture Partners
Rho Ventures
Rho Capital Partners
Series B+ 3 investors entered at this stage
TopSpin Marketing Group, Inc.
Solon Mack Capital
Merck & Co.

Global footprint

Where NGM Biopharmaceuticals has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
4K monthly visits
across markets
🇺🇸 United States77.5%
🇮🇳 India22.5%
Top 2 markets shown

Patent intelligence

$86M patent portfolio · 41 active families

Estimated portfolio value
$86M
4.2× larger than top peer Dianthus Therapeutics ($21M)
41 active patent families
Where NGM Biopharmaceuticals innovates Antiendomysial antibodiesCell biologyDiseaseFGF19Fibrocyte

Where NGM Biopharmaceuticals concentrates vs peers

Each axis is a top-10 topic across NGM Biopharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about NGM Biopharmaceuticals

An AI-synthesized read of the highest-engagement posts about NGM Biopharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NGM Biopharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.